
Cytokinetics (CYTK) Stock Forecast & Price Target
Cytokinetics (CYTK) Analyst Ratings
Bulls say
Cytokinetics is supported by a strong commercial launch for MYQORZO, with U.S. revenue of $43.1M in 3Q26, about 2,800 patients dispensed therapy, and >80% of prescriptions paid, while market share approached 45% and commercial coverage exceeded 60%. Its outlook is further strengthened by a large, underpenetrated HCM market, differentiated clinical data in both oHCM and nHCM, and a broad label expansion opportunity, including MAPLE-HCM with PDUFA set for November 14, 2026 and an nHCM sNDA expected in 4Q26. The company also has expanding international momentum, with approvals in China, the U.S., the EU, the UK, Germany, and Canada, and its pipeline value is anchored by aficamten, which represents 76% of the valuation.
Bears say
Cytokinetics is viewed negatively because its lead asset, aficamten (Myqorzo), faces meaningful clinical and regulatory risk in nHCM, while omecamtiv mecarbil or ulacamten could still fail in ongoing studies. Safety data already show LVEF <50% in 10.5% of aficamten patients versus 0.8% on placebo, with two serious HF events tied to reduced LVEF and ten additional serious HF events, underscoring a narrow therapeutic window. Commercially, even if approved, uptake could be constrained by reimbursement hurdles in Europe or China, restrictive U.S. payer coverage, and a lack of clear differentiation versus mavacamten, limiting meaningful market share.
This aggregate rating is based on analysts' research of Cytokinetics and is not a guaranteed prediction by Public.com or investment advice.
Cytokinetics (CYTK) Analyst Forecast & Price Prediction
Start investing in Cytokinetics (CYTK)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Cytokinetics (CYTK) Forecast
Cytokinetics (CYTK) Analyst Forecast & Price Prediction
Start investing in Cytokinetics (CYTK)
Order type
Buy in
Order amount
Est. shares
0 shares